Investors’ outlook regarding the stock price performance over the year has been split, with some feeling optimistic and others feeling pessimistic, as it’s been a mixed bag. Year to date metric has recorded a gain of 28.99%.However, over the last six months, we can see a stronger performance of -31.09%. Over the last 30 days, the price of UNCY has leaped by -7.90%. And in the last five days, it has surged by 1.75%.
At present, Unicycive Therapeutics Inc (UNCY) has a stock price of $4.08. In the previous session, the stock saw a rise, peaking at $105.0 after an opening price of $4.08. The day’s lowest price was $30.0, and it closed at $4.7.
Unicycive Therapeutics Inc experienced a somewhat shaky performance in the stock market. The company’s stock reached a 1-year high of $11.00 on 06/09/25, while the lowest price for the same period was registered at $2.75 on 09/04/24.
52-week price history of UNCY Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Unicycive Therapeutics Inc’s current trading price is -62.91% away from its 52-week high, while its distance from the 52-week low is 48.36%. The stock’s price range during this period has varied between$2.75 and $11.00. The Unicycive Therapeutics Inc’s shares, which operate in the Healthcare, saw a trading volume of around 2.13 million for the day, a figure considerably higher than their average daily volume of 0.74 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Unicycive Therapeutics Inc (UNCY) has experienced a quarterly decline of -31.53% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 72.06M and boasts a workforce of 22 employees.
Unicycive Therapeutics Inc: Analysts’ Ratings Unveiled
As of right now, 5 analysts are rating Unicycive Therapeutics Inc as a BUY, 3 of the polled analysts branded the stock as an OVERWEIGHT, 0 analyst is recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 5.62, with a change in price of -2.28. Similarly, Unicycive Therapeutics Inc recorded 523,038 in trading volume during the last 100 days, posting a change of -35.81%.
UNCY’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for UNCY stands at 0.02. Similarly, the long-term debt-to-equity ratio is also 0.00.
UNCY Stock Stochastic Average
Unicycive Therapeutics Inc’s raw stochastic average for the past 50 days is presently 3.08%, as of today. This marks a decrease from the raw stochastic average of the last 20 days, which was 19.82%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 53.16% and 53.67%, respectively.
